Compare PESI & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | TNYA |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.8M | 204.8M |
| IPO Year | 1992 | 2021 |
| Metric | PESI | TNYA |
|---|---|---|
| Price | $13.36 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 184.4K | ★ 2.5M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,661,000.00 | N/A |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $82.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.25 | $0.36 |
| 52 Week High | $16.50 | $4.01 |
| Indicator | PESI | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 47.72 |
| Support Level | $12.02 | $1.21 |
| Resistance Level | $12.75 | $1.43 |
| Average True Range (ATR) | 0.66 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 81.44 | 43.59 |
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.